AACR 2021 | Oleclumab plus osimertinib for advanced EGFRm NSCLC
Xiuning Le, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of the findings of a Phase Ib/II trial (NCT03381274) of the CD73 inhibitor oleclumab in combination with osimertinib for the treatment of advanced mutant EGFR (EGFRm) non-small cell lung cancer (NSCLC). The study reported that oleclumab and osimertinib combination therapy was well tolerated at the recommended Phase II dose. The overall response rate to oleclumab plus osimertinib was similar to previous results of osimertinib monotherapy at 21% versus 19% respectively, but oleclumab plus osimertinib achieved a longer median progression-free survival of 11 months versus 2.8 months. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.
Disclosures
Xiuning Le, MD, PhD, has received consulting/advisory fees from EMD Serono (Merck KGaA), AstraZeneca, Spectrum Pharmaceutics, Eli Lilly, Boehringer Ingelheim, Bristol-Myers Squibb and Celgene; and has received research funding from Eli Lilly and Boehringer Ingelheim.
